Synopsis: Bernard Coulie is the President and CEO of Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately preserving organ function. Bernard discusses the arc of his career and shares his perspective on the European biotech ecosystem compared to the United States, and how that’s changed over the last 10 years. He talks about the importance of having access to lots of capital in the early days of starting a company. He discusses fibrotic disease, the high medical need to treat it, and the indications they are pursuing. Finally, he discusses the challenges of focusing on multiple therapeutic areas and the advice he would give to others. Biography: Pliant CEO Bernard Coulie, M.D., Ph.D., brings to the company more than 15 years of senior leadership experience and drug development expertise. He joined Pliant from ActoGeniX (acquired by Intrexon Corporation in February 2015), where he was CEO, Chief Medical Officer and Co-Founder. In these positions, Dr. Coulie played an integral role in advancing the company’s unique technology platform for oral delivery of biologics from early discovery stage through Phase 2 studies. Prior to ActoGeniX, Dr. Coulie held various positions with increasing responsibilities in drug discovery and clinical development at Johnson & Johnson Pharmaceutical Research and Development Europe. At Johnson & Johnson, he served as Therapeutic Area Leader Internal Medicine, managing a portfolio of products in GI, metabolic diseases and inflammation/immunology, ranging from early drug discovery through Phase 2 studies. Earlier in his career, Dr. Coulie was a Staff Physician in the Department of Gastroenterology and Hepatology at Mayo Clinic (Rochester, MN), Assistant Professor in Medicine at Mayo Medical School and a Mayo Foundation scholar. Dr. Coulie serves as Chairman of the Board of Directors of SQZ Biotechnologies, a publicly-traded cell therapy biotechnology company, as Independent Chairman of Dualyx, a privately-held biotechnology company based in Belgium and as an Independent Director at Calypso Biotech, a privately-held biotechnology company based in the Netherlands. Dr. Coulie holds an M.D. and Ph.D. from the University of Leuven, Belgium. He is a board-certified internist and holds an MBA from the Vlerick Management School, Leuven, Belgium.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related